Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label dose-comparison study of mefatinib 60 mg versus 80 mg as first-line therapy for EGFR-mutant advanced non-small cell lung cancer
ChiCTR2000029059Phase 2Completed
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of maihuatinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Progression-free survival. Started Jul 2018; status: completed.
02
Drugs
maihuatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029059.